Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.20) per share. This is a 300 percent decrease over losses of $(0.05) per share from the same period last year. The company reported $142.00 thousand in sales this quarter. This is a 99.10 percent decrease over sales of $15.73 million the same period last year.